What We Do

The Experimental Therapeutics Research Laboratory, under the direction of Robert A. Floyd, Ph.D., focuses on new discoveries in biomedical research and their role in the development of novel therapeutic approaches for treating important human diseases. At this critical interface, which is often underserved in the biomedical research arena, researchers can pose creative new scientific questions and conduct experiments to evaluate if novel therapeutics can arise.
With over 20 years of experience working in both basic biomedical science and the development of novel therapeutics, the scientists in this program have helped to develop agents to effectively photo-inactivate important RNA viruses, including HIV and West Nile viruses. Their research also has led to the discovery that nitrones are effective in preventing brain damage caused by stroke in experimental animals. As a result of these discoveries, specific nitrones underwent 12 years of commercial development—leading to Phase III clinical trials—for the treatment of stroke.
Current research projects focus on specific nitrones for the treatment of cancers and the mechanistic basis of their anti-cancer activity. Specifically, these experiments center on developing novel therapeutics for cancers, including glioblastoma and pancreatic cancer, where no effective therapeutics now exist.
For more information, please contact:
Robert A. Floyd, Ph.D., Program Head
Experimental Therapeutics Research Program
Oklahoma Medical Research Foundation
825 Northeast 13th Street
Oklahoma City, OK 73104
Phone: 405-271-7580
Fax: 405-271-1795
Email: floydr@omrf.org
Our Publications

2011
Bhattacharjee S, Deterding LJ, Chatterjee S, Jiang J, Ehrenshaft M, Lardinois O, Ramirez DC, Tomer KB, Mason RP. Site-specific radical formation in DNA induced by Cu(II)-H(2)O(2) oxidizing system, using ESR, immuno-spin trapping, LC-MS, and MS/MS. Free Radic Biol Med 50:1536-1545, 2011. [Abstract]
Choi CH, Chen K, Du X, Floyd RA, Kopke RD. Effects of delayed and extended antioxidant treatment on acute acoustic trauma. Free Radic Res 45:1162-1172, 2011. [Abstract]
Du X, Choi CH, Chen K, Cheng W, Floyd RA, Kopke RD. Reduced formation of oxidative stress biomarkers and migration of mononuclear phagocytes in the cochleae of chinchilla after antioxidant treatment in acute acoustic trauma. Int J Otolaryngol 2011:612690, 2011. [Abstract]
* Floyd RA, Chandru HK, He T, Towner R. Anti-cancer activity of nitrones and observations on mechanism of action. Anticancer Agents Med Chem 11:373-379, 2011. [Abstract]
* Floyd RA, Towner RA, He T, Hensley K, Maples KR. Translational research involving oxidative stress and diseases of aging. Free Radic Biol Med 51:931-941, 2011. [Abstract]
* He T, Doblas S, Saunders D, Casteel R, Lerner M, Ritchey JW, Snider T, Floyd RA, Towner RA. Effects of PBN and OKN007 in rodent glioma models assessed by (1)H MR spectroscopy. Free Radic Biol Med 51:490-502,2011. [Abstract]
Mandal MN, Moiseyev GP, Elliott MH, Kasus-Jacobi A, Li X, Chen H, Zheng L, Nikolaeva O, Floyd RA, Ma JX, Anderson RE. {alpha}-phenyl-N-tert-butyl nitrone (PBN) prevents light-induced degeneration of the retina by inhibiting RPE65 protein isomerohydrolase activity. J Biol Chem 286:32491-32501, 2011. [Abstract]
2012
Du X, Chen K, Choi CH, Li W, Cheng W, Stewart C, Hu N, Floyd RA, Kopke RD. Selective degeneration of synapses in the dorsal cochlear nucleus of chinchilla following acoustic trauma and effects of antioxidant treatment. Hear Res 283:1-13, 2012. [Abstract]
* Indicates publications by more than one department.
Contact Us

Robert A. Floyd, Ph.D., Program Head
Experimental Therapeutics Research Program
Oklahoma Medical Research Foundation
825 Northeast 13th Street
Oklahoma City, OK 73104
Phone: (405) 271-7580
Fax: (405) 271-1795
Email: Robert-Floyd@omrf.org





